244 related articles for article (PubMed ID: 30594550)
1. Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer.
Tong M; Yu C; Zhan D; Zhang M; Zhen B; Zhu W; Wang Y; Wu C; He F; Qin J; Li T
EBioMedicine; 2019 Feb; 40():305-317. PubMed ID: 30594550
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer.
Tong M; Yu C; Shi J; Huang W; Ge S; Liu M; Song L; Zhan D; Xia X; Liu W; Feng J; Shi W; Ji J; Gao J; Shi T; Zhu W; Ding C; Wang Y; He F; Shen L; Li T; Qin J
iScience; 2019 Dec; 22():44-57. PubMed ID: 31751824
[TBL] [Abstract][Full Text] [Related]
3. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
4. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
5. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.
Francavilla C; Lupia M; Tsafou K; Villa A; Kowalczyk K; Rakownikow Jersie-Christensen R; Bertalot G; Confalonieri S; Brunak S; Jensen LJ; Cavallaro U; Olsen JV
Cell Rep; 2017 Mar; 18(13):3242-3256. PubMed ID: 28355574
[TBL] [Abstract][Full Text] [Related]
7. Impact of phosphoproteomics in the translation of kinase-targeted therapies.
Casado P; Hijazi M; Britton D; Cutillas PR
Proteomics; 2017 Mar; 17(6):. PubMed ID: 27774731
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
Andorfer P; Heuwieser A; Heinzel A; Lukas A; Mayer B; Perco P
BMC Syst Biol; 2016 Apr; 10():33. PubMed ID: 27090655
[TBL] [Abstract][Full Text] [Related]
9. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
10. Unraveling Kinase Activation Dynamics Using Kinase-Substrate Relationships from Temporal Large-Scale Phosphoproteomics Studies.
Domanova W; Krycer J; Chaudhuri R; Yang P; Vafaee F; Fazakerley D; Humphrey S; James D; Kuncic Z
PLoS One; 2016; 11(6):e0157763. PubMed ID: 27336693
[TBL] [Abstract][Full Text] [Related]
11. Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.
Faratian D; Um I; Wilson DS; Mullen P; Langdon SP; Harrison DJ
Eur J Cancer; 2011 Jun; 47(9):1420-31. PubMed ID: 21334202
[TBL] [Abstract][Full Text] [Related]
12. From Phosphosites to Kinases.
Munk S; Refsgaard JC; Olsen JV; Jensen LJ
Methods Mol Biol; 2016; 1355():307-21. PubMed ID: 26584935
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers.
Farinella F; Merone M; Bacco L; Capirchio A; Ciccozzi M; Caligiore D
Sci Rep; 2022 Feb; 12(1):3041. PubMed ID: 35197484
[TBL] [Abstract][Full Text] [Related]
14. Phosphoproteomics for oncology discovery and treatment.
Stern DF
Expert Opin Ther Targets; 2005 Aug; 9(4):851-60. PubMed ID: 16083347
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics Analysis of Global Proteomic and Phosphoproteomic Data Sets Revealed Activation of NEK2 and AURKA in Cancers.
Deb B; Sengupta P; Sambath J; Kumar P
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32033228
[TBL] [Abstract][Full Text] [Related]
16. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
17. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
18. Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine.
Wu X; Xing X; Dowlut D; Zeng Y; Liu J; Liu X
J Proteomics; 2019 Jan; 191():68-79. PubMed ID: 29621648
[TBL] [Abstract][Full Text] [Related]
19. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Khorsandi SE; Dokal AD; Rajeeve V; Britton DJ; Illingworth MS; Heaton N; Cutillas PR
Cancer Res; 2021 Nov; 81(22):5765-5776. PubMed ID: 34551960
[TBL] [Abstract][Full Text] [Related]
20. Tracing cancer networks with phosphoproteomics.
Solit DB; Mellinghoff IK
Nat Biotechnol; 2010 Oct; 28(10):1028-9. PubMed ID: 20944590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
